EUVIMEDEUVIMED entdecken
Crossref

Altered epitopes enhance macrophage‐mediated anti‐tumour immunity to low‐immunogenic tumour mutations

Qiumin Yu iD, Tingran Zhang, Tiandi He, Yifan Yang, Wanli Zhang, Yanliang Kang, Zijie Wu, Wenbin Xie, Jiaxue Zheng, Qianqian Qian, Guozhi Li, Di Zhang und 15 weitere

Immunology · 2024

DOI: 10.1111/imm.13854 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Qiumin Yu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, Ch…. Hauptthemen laut MEDLINE: Cancer Vaccines, Mutation, CD8-Positive T-Lymphocytes, Antigens, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Key R&D Program of Xinjiang Uygur Autonomous Region, the Open Project of NMPA Key Laboratory for Impurity Profile of Chemical Drugs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Personalized neoantigen therapy has shown long‐term and stable efficacy in specific patient populations. However, not all patients have sufficient levels of neoantigens for treatment. Although somatic mutations are commonly found in tumours, a significant portion of these mutations do not trigger an immune response. Patients with low mutation burdens continue to exhibit unresponsiveness to this treatment. We propose a design paradigm for neoantigen vaccines by utilizing the highly immunogenic unnatural amino acid p‐nitrophenylalanine (pNO 2 Phe) for sequence alteration of somatic mutations that failed to generate neoepitopes. This enhances the immunogenicity of the mutations and transforms it into a suitable candidate for immunotherapy. The nitrated altered epitope vaccines designed according to this paradigm is capable of activating circulating CD8 + T cells and inducing immune cross‐reactivity against autologous mutated epitopes in different MHC backgrounds (H‐2K b , H‐2K d , and human HLA‐A02:01), leading to the elimination of tumour cells carrying the mutation. After immunization with the altered epitopes, tumour growth was significantly inhibited. It is noteworthy that nitrated epitopes induce tumour‐infiltrating macrophages to differentiate into the M1 phenotype, surprisingly enhancing the MHC II molecule presenting pathway of macrophages. Nitrated epitope‐treated macrophages have the potential to cross‐activate CD4 + and CD8 + T cells, which may explain why pNO 2 Phe can enhance the immunogenicity of epitopes. Meanwhile, the immunosuppressive microenvironment of the tumour is altered due to the activation of macrophages. The nitrated neoantigen vaccine strategy enables the design of vaccines targeting non‐immunogenic tumour mutations, expanding the pool of potential peptides for personalized and shared novel antigen therapy. This approach provides treatment opportunities for patients previously ineligible for new antigen vaccine therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesMutationCD8-Positive T-LymphocytesAntigens, NeoplasmNeoplasmsHumansAnimalsMiceEpitopesCell Line, TumorMacrophagesTumor MicroenvironmentImmunotherapyMice, Inbred C57BLEpitopes, T-LymphocyteHLA-A2 Antigen

Stichwörter der Autor:innen

cancer vaccinesmacrophage activationneoantigensunnatural amino acid

Substanzen

Cancer VaccinesAntigens, NeoplasmEpitopesEpitopes, T-LymphocyteHLA-A2 Antigen

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
  • Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, China.
  • Department of General Internal Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

ORCID-Profile: Qiumin Yu, Ximing Li, Hong Tian

Förderung

  • National Natural Science Foundation of China
  • the Key R&D Program of Xinjiang Uygur Autonomous Region
  • the Open Project of NMPA Key Laboratory for Impurity Profile of Chemical Drugs

Zitieren

APA

Yu, Q., Zhang, T., He, T., Yang, Y., Zhang, W., Kang, Y., Wu, Z., Xie, W., Zheng, J., Qian, Q., Li, G., Zhang, D., Mao, Q., Gao, Z., Wang, X., Shi, X., Huang, S., Guo, H., Zhang, H., …, & Tian, H. (2024). Altered epitopes enhance macrophage‐mediated anti‐tumour immunity to low‐immunogenic tumour mutations. Immunology. https://doi.org/10.1111/imm.13854

Vancouver

Yu Q, Zhang T, He T, Yang Y, Zhang W, Kang Y, et al. Altered epitopes enhance macrophage‐mediated anti‐tumour immunity to low‐immunogenic tumour mutations. Immunology. 2024. doi:10.1111/imm.13854

BibTeX
@article{Yu2024,
  author = {Yu, Qiumin and Zhang, Tingran and He, Tiandi and Yang, Yifan and Zhang, Wanli and Kang, Yanliang and Wu, Zijie and Xie, Wenbin and Zheng, Jiaxue and Qian, Qianqian and Li, Guozhi and Zhang, Di and Mao, Qiuli and Gao, Zheng and Wang, Xiaoning and Shi, Xupeiyao and Huang, Shitong and Guo, Hanlin and Zhang, Haoyu and Chen, Lingxiao and Li, Ximing and Deng, Danni and Zhang, Li and Tong, Yue and Yao, Wenbing and Gao, Xiangdong and Tian, Hong},
  title = {Altered epitopes enhance macrophage‐mediated anti‐tumour immunity to low‐immunogenic tumour mutations},
  journal = {Immunology},
  year = {2024},
  doi = {10.1111/imm.13854}
}
Kostenlos starten →